{"groups":[{"description":"Metastatic breast cancer\n\nPD-0332991: Given orally, 125 mg QD on a 21-day","id":"FG000","title":"Arm 1"},{"description":"Metastatic colorectal cancer that harbors the Kras or BRAF mutation\n\nPD-0332991: Given orally, 125 mg QD on a 21-day","id":"FG001","title":"Arm 2"},{"description":"Advanced or metastatic esophageal and/or gastric cancer\n\nPD-0332991: Given orally, 125 mg QD on a 21-day","id":"FG002","title":"Arm 3"},{"description":"Cisplatin-refractory, unresectable germ cell tumors\n\nPD-0332991: Given orally, 125 mg QD on a 21-day","id":"FG003","title":"Arm 4"},{"description":"Any tumor type if tissue tests positive for CCND1 amplification, CDK4/6 mutation , CCND2 amplification OR any other functional alteration at the G1/S checkpoint.\n\nPD-0332991: Given orally, 125 mg QD on a 21-day","id":"FG004","title":"Arm 5"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"63"},{"groupId":"FG001","numSubjects":"18"},{"groupId":"FG002","numSubjects":"19"},{"groupId":"FG003","numSubjects":"30"},{"groupId":"FG004","numSubjects":"11"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"63"},{"groupId":"FG001","numSubjects":"18"},{"groupId":"FG002","numSubjects":"19"},{"groupId":"FG003","numSubjects":"30"},{"groupId":"FG004","numSubjects":"11"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}